Accel Wealth Management’s Anixa Biosciences ANIX Stock Holding History

Accel Wealth Management’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,250	Closed	-$3K	–	1018
2022 Q1	$3K	Hold	1,250	–	–	﹤0.01%	846
2021 Q4	$4K	Buy	+1,250	New	+$5.05K	﹤0.01%	834
2021 Q3	–	Sell	-1,250	Closed	-$5K	–	824
2021 Q2	$5K	Hold	1,250	–	–	﹤0.01%	787
2021 Q1	$6K	Buy	+1,250	New	+$5.97K	﹤0.01%	717

Other funds holding ANIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Accel Wealth Management's ANIX Position: Q2 2022 in Review

Accel Wealth Management sold out of Anixa Biosciences (ANIX) in Q2 2022, closing a stake of 1,250 shares — an estimated $3K sold.

Accel Wealth Management first reported a position in ANIX in Q1 2021 and held it in 4 quarters. The position peaked at $6K in Q1 2021. 45 funds tracked by Wall St. Rank hold ANIX as of Q2 2022.

Accel Wealth Management reported no remaining Anixa Biosciences position as of Q2 2022 after selling out during the quarter.
Accel Wealth Management sold 1,250 Anixa Biosciences shares in Q2 2022, an estimated $3K.
Accel Wealth Management first reported a position in Anixa Biosciences in Q1 2021 and held it in 4 quarters.
Accel Wealth Management's Anixa Biosciences position peaked at $6K in Q1 2021.
45 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2022.

Based on Accel Wealth Management's 13F filing for Q2 2022, filed 3 Aug 2022.